EA
eat_dis_watermelon
Community Contributor
Member since 2022
Views3.7kTotal number of views
Followers36Total number of followers
Comments1Total number of comments
No bio added yet
No link added
Eli Lilly's Future Growth Driven by Tirzepatide and Favorable Market Conditions
Catalysts Mounjaro/Zepbound: Lilly’s tirzepatide franchise is the engine of growth. Mounjaro (for type 2 diabetes) and Zepbound (obesity) each grew rapidly in 2024.Read more
3.7k
users have viewed this narrative9users have liked this narrative
2users have commented on this narrative
37users have followed this narrative
EA
US$1.19k
12.4% undervalued intrinsic discount
eat_dis_watermelon's Fair Value
Revenue
20% p.a.
Profit Margin
25.91%
Future PE
49.63x
Price in 2030
US$1.92k